Report date: Apr 30, 2024 Conflict count: 350192 Publisher: Research Desk Inc Title count: 5 Conflict count: 13 ========================================================== Created: 2020-10-26 11:40:32.0 ConfID: 5719651 CauseID: 1480646087 OtherID: 1473407292 JT: Cancer Studies and Therapeutics MD: null, 2 ,1,null,2017,Revisiting ‘what causes cancer?’ DOI: 10.31038/CST.2017101(Journal) (5719651-N ) DOI: 10.31038/CST.2017211(Journal) ========================================================== Created: 2020-10-26 11:43:41.0 ConfID: 5719670 CauseID: 1480646245 OtherID: 1473407318 JT: Cancer Studies and Therapeutics MD: null, 2 ,1,null,2017,Platinum Plus Gemcitabine as the Most Effective Regimen in the First Line of Chemotherapy in Advanced Squamous Cell Lung Cancer DOI: 10.31038/CST.2017102(Journal) (5719670-N ) DOI: 10.31038/CST.2017212(Journal) ========================================================== Created: 2020-10-26 11:46:41.0 ConfID: 5719695 CauseID: 1480647050 OtherID: 1473407356 JT: Cancer Studies and Therapeutics MD: null, 2 ,1,null,2017,Long Term Results of High Dose Rate Brachytherapy and External Beam Radiotherapy for Local and Locally Advanced Prostate Cancer DOI: 10.31038/CST.2017103(Journal) (5719695-N ) DOI: 10.31038/CST.2017213(Journal) ========================================================== Created: 2020-10-26 11:49:11.0 ConfID: 5719696 CauseID: 1480648398 OtherID: 1473407425 JT: Cancer Studies and Therapeutics MD: null, 2 ,1,null,2017,Overexpression of IFN-γR Increases the Radiotherapy Resistance of Nasopharyngeal Carcinoma DOI: 10.31038/CST.2017104(Journal) (5719696-N ) DOI: 10.31038/CST.2017214(Journal) ========================================================== Created: 2020-10-26 11:51:39.0 ConfID: 5719697 CauseID: 1480648476 OtherID: 1473407458 JT: Cancer Studies and Therapeutics MD: null, 2 ,1,null,2017,Activation of STAT3 and its impacts on Proteasome Inhibitor-Induced Apoptosis in Laryngeal Sqaumous Carcinoma DOI: 10.31038/CST.2017105(Journal) (5719697-N ) DOI: 10.31038/CST.2017215(Journal)